Article

timesofisrael.comtimesofisrael.com on 2018-09-16 10:38

Teva shares rally as FDA approves troubled drugmaker’s migraine treatment

Ajovy seen as key to helping firm reverse fortunes as sales decline for flagship drug Copaxone for multiple sclerosis; competition expected to arrive soon

Related news